Company Description
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis.
The company’s lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer’s disease and Parkinson’s disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase.
The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026.
LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Mark Litton |
Contact Details
Address: 18706 North Creek Parkway, Suite 104 Bothell, Washington 98011 United States | |
| Phone | 425 620 8501 |
| Website | leonabio.com |
Stock Details
| Ticker Symbol | LONA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001620463 |
| CUSIP Number | 04746L203 |
| ISIN Number | US04746L2034 |
| Employer ID | 45-3368487 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark J. Litton M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Mark F. Worthington J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Dr. Javier San Martin M.D. | Chief Medical Officer |
| Robert Renninger | Chief Financial Officer |
| Dr. Kevin Church Ph.D. | Chief Scientific Officer |
| Julie Rathbun | Head of Investor Relations |
| Mark F. Kubik M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 11, 2026 | ARS | Filing |
| May 11, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 11, 2026 | DEF 14A | Other definitive proxy statements |
| May 7, 2026 | SCHEDULE 13D/A | Filing |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 2, 2026 | 424B3 | Prospectus |
| Apr 2, 2026 | 424B3 | Prospectus |